India's Bharat Biotech says COVID-19 vaccine shows 81% interim efficacy

DIBYANGSHU SARKAR / AFP

Bharat Biotech's homegrown COVID-19 vaccine has shown an interim vaccine efficacy of 81% in late-stage clinical trials, the Indian company said on Wednesday.

The interim analysis was based on 43 recorded cases of COVID-19 in the trial of 25,800 participants, conducted in partnership with the Indian government's medical research body.

Thirty-six of the 43 cases were recorded in participants who received a placebo, compared with seven cases in people who were given the Bharat Biotech vaccine, pointing to an efficacy rate of 80.6%, the company said.

India had approved the vaccine, branded COVAXIN, in January without late-stage efficacy data, raising questions about its effectiveness.

India's vaccination drive, currently underway, includes COVAXIN and a vaccine developed by Oxford University and AstraZeneca.

Earlier this week, Indian Prime Minister Narendra Modi was inoculated with the first dose of COVAXIN.

More from International News

On Virgin Radio today

Trending on Virgin Radio

  • BRED Abu Dhabi

    BRED Abu Dhabi, Presented by Hypebeast, is back April 24-28 in Yas Bay. The line up is next level and locked in.

  • Middle East Hot 30

    Every weekend Kris Fade plays the biggest tracks in the Middle East. Check out this weeks chart...

  • Ed Sheeran - UAE EXCLUSIVE

    Latest album, what happened with BTS, raising a baby girl, eye surgery, and more!

  • Mais Vault on the Kris Fade Show!

    The boys tried their 'pick up' lines on Mais Vault and things did not go according to plan...